secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001493152-23-007607
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage appoints Jerry He as CEO, replacing David Green; sets compensation terms
--------------------------------------------------------------------------------

- Jerry He appointed Chairman and CEO effective March 1, 2023; David Green remains on board.
- Base salary $300,000, rising to $500,000 if private placement raises ≥$4M.
- Time-based option grant: 732,384 shares; milestone grant up to 488,256 shares.
- If offering raises <$4M, annual option grant valued at $200,000 in lieu of additional cash.
- Annual bonus up to 100% of base salary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223007607/0001493152-23-007607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223007607/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer